Urinary Tract Infection Treatment Global Market Report 2024

The urinary tract infection treatment market size has grown steadily in recent years. It will grow from $10.12 billion in 2023 to $10.45 billion in 2024 at a compound annual growth rate (CAGR) of 3.3%. The expansion observed in the historical period can be attributed to discoveries in antibiotics, the use of urinary catheters, the implementation of clinical guidelines and protocols, increased patient awareness and education, and advancements in women's health research.

The urinary tract infection treatment market size is expected to see steady growth in the next few years. It will grow to $11.74 billion in 2028 at a compound annual growth rate (CAGR) of 2.9%. The anticipated growth in the forecast period can be attributed to the development of non-antibiotic treatments, the rise in resistant bacterial strains, the adoption of personalized treatment approaches, the utilization of telemedicine and remote consultations, and public health awareness programs. Prominent trends expected during the forecast period include the emergence of microbiome-based therapies, the exploration of phage therapy, the implementation of point-of-care testing, the consideration of nutritional interventions, a focus on preventive strategies, and the development of community-based interventions.

The increasing prevalence of urinary tract infections is poised to drive the expansion of the market for urinary tract infection treatment in the future. Urinary tract infections encompass bacterial infections affecting various parts of the urinary system, including the kidneys, bladder, ureters, and urethra. Effective treatment of urinary tract infections is crucial in addressing the infection and fostering healing. As of January 2023, the National Institute of Health reported that urinary tract infections ranked as the seventh most common reason for emergency department visits in the USA, constituting over one million annual visits. Of these cases, 22% (220,000) were considered complicated UTIs, with around 100,000 resulting in hospital admissions. Consequently, the increasing prevalence of urinary tract infections is a significant driver of growth in the urinary tract infection treatment market.

The aging population is anticipated to be a catalyst for the expansion of the urinary tract infection treatment market. The term 'aging population' refers to a demographic shift characterized by a rising proportion of elderly individuals within a society or population. The elderly demographic requires urinary tract infection (UTI) treatment due to an elevated susceptibility to UTIs associated with age-related factors such as weakened immune function and alterations in urinary tract structure. As of October 2022, the World Health Organization highlighted that the global population of individuals aged 60 years and older is rapidly growing, projected to double by 2050, reaching 2.1 billion. Hence, the increasing aging population is propelling the growth of the urinary tract infection treatment market.

The adoption of advanced diagnostic technologies is an emerging trend gaining traction in the urinary tract infection treatment market. Companies in the market are focusing on innovative product development to maintain their competitive positions. In April 2023, AccessDx Laboratory, a US-based diagnostic laboratory, introduced the UTI PROx Panel. UTI PROx is designed to provide healthcare providers with enhanced insights to improve clinical care and decision-making when dealing with suspected, complex, and recurrent urinary tract infections.

Major companies operating in the urinary tract infection treatment market are concentrating on the development of innovative products such as Harncare bearberry tablets. These tablets serve as an herbal remedy for symptoms associated with lower urinary tract infections. Harncare Bearberry Tablets, formulated with the single crude drug bearberry, is the first tablet of its kind in Japan and is available as a second-class over-the-counter drug in pharmacies and drugstores across the country. In March 2022, Taiho Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, launched Harncare Bearberry tablets, addressing urinating discomfort and the sensation of residual urine.

In July 2021, Pharmavite, a US-based dietary supplement company, completed the acquisition of Uqora for an undisclosed amount. This strategic move enabled Pharmavite to enhance its solutions in the women’s health space. Uqora, a US-based natural supplement company, specializes in developing supplements and reactive solutions designed to reduce the risk of urinary tract infections (UTIs).

Major companies operating in the urinary tract infection treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Allergan PLC, Bayer AG, Novartis International AG., Sanofi S.A., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Bio-Rad Laboratories Inc., Cipla Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Almirall SA, Torrent Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Mylan N.V.

North America was the largest region in the urinary tract infection treatment market in 2023. The regions covered in the urinary tract infection treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urinary tract infection treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of drug classes in urinary tract infection treatment include penicillin and combinations, quinolones, cephalosporin, aminoglycoside antibiotics, Sulfonamides, azoles and amphotericin B, tetracycline, and nitrofurantoin. Penicillin, a beta-lactamase antibacterial medication, is utilized to manage a wide range of infections, including urinary tract infections (UTIs). It is effective against common bacteria causing UTIs and is generally well-tolerated. Indications for penicillin in urinary tract infection treatment include both complicated and uncomplicated UTIs. Distribution channels encompass hospital pharmacies, gynecology and urology clinics, drug stores, retail pharmacies, and online drug stores.

The urinary tract infection treatment market research report is one of a series of new reports that provides urinary tract infection treatment market statistics, including the urinary tract infection treatment industry global market size, regional shares, competitors with a urinary tract infection treatment market share, detailed urinary tract infection treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the urinary tract infection treatment industry. This urinary tract infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urinary tract infection treatment market consists of sales of trimethoprim, sulfamethoxazole, cephalexin, and ceftriaxone. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.